T he MTP is a heterodimer of the larger and unique 97-kDa subunit and the multifunctional 55-kDa protein disulfide isomerase. 1 Functional MTP is an absolute requirement for the assembly and cellular secretion of apoB-containing lipoproteins. Cells that normally do not secrete apoB can acquire this competence if the genes encoding apoB and MTP are provided by gene transfection, as shown in HeLa cells and COS-1 cells. 2, 3 Conversely, if MTP activity is inhibited in cells that normally do secrete apoB-containing lipoproteins, the secretion of apoB is drastically reduced. 4, 5 A complete lack of MTP activity leads to abetalipoproteinemia, 6 a disease caused by mutations in the coding region of the MTP gene. [7] [8] [9] The promoter region of the MTP gene is highly conserved between species and shows signs of both cell type-specific expression and response to metabolic regulators. The activity of the human MTP promoter is suppressed by insulin and enhanced by cholesterol. 10 The insulin response has been confirmed in HepG2 cells. 11 It has also been shown that hamsters fed either a high-fat or a cholesterol-enriched diet have higher concentrations of MTP mRNA.
Against this background we hypothesized that genetic variation in MTP expression might influence the plasma concentrations of apoB-containing lipoproteins in humans. We report herein a common functional polymorphism in the promoter region of the MTP gene, of which the rarer allele is linked to low plasma LDL cholesterol concentrations.
Methods

Human Subjects
A total of 184 healthy white men, aged 30 to 45 years, were recruited at random from a register containing all permanent residents of the Stockholm metropolitan area (response rate of 70%). Men with documented coronary heart disease or any other chronic disease were excluded. The mean age of the study group was 40.3Ϯ3.4 years, and the body mass index was 24.5Ϯ2.8 kg/m 2 . Fifteen subjects from the group of 184 with selected MTP promoter genotypes were asked to return for a detailed compositional analysis of fasting plasma VLDL. The procedures described in this study have been approved by the Karolinska Hospital Ethics Committee.
Blood Sampling, DNA Procedures, and Lipoprotein Analyses
Blood sampling, preparation of plasma, and quantification of major fasting plasma lipoproteins were performed as described previously. 12 For DNA procedures, nucleated cells from frozen whole blood were prepared according to Sambrook et al, 13 and DNA was extracted by a salting-out method.
14 All subjects were also genotyped for the apoE polymorphism. 15 VLDL subfractions were isolated from fasting plasma, and the content of apoB-100 was quantified by analytical SDS-polyacrylamide gel electrophoresis as described. 16 
Gene Sequencing
DNA for direct sequencing of the MTP promoter was amplified in a two-step nested PCR reaction. Approximately 100 ng of genomic DNA was used for each individual PCR reaction. Primers were designed from the published promoter sequence (Ϫ743 bp in the 5Ј direction). 7 First, a round of PCR was performed by using the primer 5Ј-CCCTCTTAATCTCTTTCCTAGAA (MTP-1) together with 5Ј-AAGAATCATATTGACCAGCAATC (MTP-2). Second, 1 L of this PCR reaction mixture was used for a second PCR that utilized one unlabeled and one biotin-labeled primer at concentrations of 0.1 mol/L each. These primers were MTP-1 and 5Ј-CCAGCTAG GAGTCACTGAGA (biotinylated). All amplifications were performed for 30 cycles at 96°C for 1 minute, 60°C for 30 seconds, and 72°C for 90 seconds in a buffer containing 1.0 mmol/L MgCl 2 , 0.2 mmol/L dNTP, 10 mmol/L Tris-HCl, pH 8.4 at 70°C, 0.1% Tween 20, and 0.2 U Taq polymerase. The biotinylated PCR fragments were immobilized by binding to streptavidin-coated magnetic beads (Dynabeads, Dynal), and the nonbiotinylated strands were removed by incubation in 50 L of 0.15 mol/L NaOH for 5 minutes at room temperature. The bound DNA was rinsed three times and resuspended in 13 L distilled water. Gene sequencing was performed with the chain-termination method using fluorescence-labeled primers distributed within the 750-bp promoter region. These were 5Ј-TAGAAATG AGATTCAGAAAGGAC (MTP-3fl), 5Ј-CAATCATCTATGTTTC ATCAA (MTP-7fl), and 5Ј-AAGTT TCCTCATTGGGTGA (MTP-8fl). The products were analyzed by using a Pharmacia ALF DNA sequencer. All primers were synthesized on a Gene Assembler Plus (Pharmacia). Labeling of primers with biotin or fluorescein was performed by incorporating BioDite or FluorePrime Fluorescein Amidite (Pharmacia), respectively, during synthesis. Fluorescence-labeled primers were purified by reversephase chromatography on a PepRPC column (Pharmacia FPLC). Normally, the sequences could be read, with a considerable overlap, thus confirming the sequence.
Genotyping
Primers MTP-1 and MTP-2 were used for genotyping of the Ϫ400 A/T polymorphism. First, a single-step PCR reaction was optimized further by increasing the MgCl 2 concentration to 2.0 mol/L and by changing the procedure to 35 cycles at 94°C for 30 seconds, 55°C for 60 seconds, and 72°C for 3 minutes. The PCR product was then incubated with the restriction enzyme Ssp1 (4 U). The Ϫ400 T allele gave rise to a cutting site. The restriction fragment length polymorphism was inspected after agarose gel (1.5%) electrophoresis of the incubate. The Ϫ400 A allele gave rise to the full-length fragment (838 bp), whereas the Ϫ400 T allele gave rise to two shorter fragments (494 and 344 bp, respectively).
The Ϫ493 G/T polymorphism does not give rise to a cutting site with any common restriction enzyme. However, a mutation in the 5Ј primer used for PCR of a gene product including the Ϫ493 site gave rise to an Hph1 cutting site for the Ϫ493 G allele. The PCR (5Ј-GGA TTTAAATTTAAACTGTTAATTCATATCAC and 5Ј-AGTTTCA CACA TAAGGACAATCATCTA) gave rise to a 109-bp fragment, and the gene product was cleaved by Hph1. For this second round of PCR, the MgCl 2 concentration was increased to 5 mmol/L and the number of cycles was changed to 35 at 94°C for 30 seconds, 57°C for 60 seconds, and 72°C for 2 minutes. The PCR product was incubated with Hph1 and the restriction fragment length polymorphism was studied after high-resolution 3% agarose gel electrophoresis (Metaphor-agarose). The Ϫ493 T allele gave rise to a full-length fragment (109 bp), whereas the Ϫ493 G allele gave rise to two fragments of 89 and 20 bp. HepG2 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum.
DNA Constructs
For the EMSA, four sets of complementary oligonucleotides were designed: Ϫ400, 5Ј-GTCCAT ACAAGAAAAATTAAAATTTG GTTAG and 5Ј-GTCCATACAAG AAATATTAAAATTTGGT TAG; and Ϫ493, 5Ј-TTGAAGTGATTGGTGGT GGTATGAAT TAACAG and 5Ј-TTGAAGTGATTGGTTGTGGTATGAATT AACAG. One set of double-stranded oligonucleotides containing the same sequences as above but flanked by BamHI and BglII ends was constructed for the CAT assay. Two double-stranded oligonucleotides were ligated head to tail into a BamHI-restricted HIV-chloramphemicol acetyl-transferase (HCAT) vector. 17 The correct sequence and orientation of the inserts were tested by DNA sequencing.
EMSA
Nuclear extracts were prepared according to Alksnis et al. 18 All buffers were freshly supplemented with leupeptin (0.7 g/mL), aprotinin (16.6 g/mL), PMSF (0.2 mol/L), and 2-mercaptoethanol (0.33 L/mL). The protein concentration in the extracts was estimated by the method of Kalb and Bernlohr. 19 Incubation for EMSA was conducted as described 20 and the reaction products were applied to a 7% (wt/vol) polyacrylamide gel (80:1 wt/wt of acrylamide/N,NЈ-methylene bisacrylamide), whereafter electrophoresis was performed in 22.5 mmol/L Tris-22.5 mmol/L boric acid-0.5 mmol/L EDTA buffer for 2.5 hours at 200 V. Nonradioactive competitor DNAs, either identical, of the opposite allelic variant, or of nonspecific origin, were added.
Transfection Assay
Twenty-four hours before transfection, cells were plated in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum. Two to 4 hours before transfection, the dishes received fresh medium. Cells were incubated for 16 hours with calcium phosphateprecipitated DNAs (15 g of plasmid per 90-mm dish). 13 After a 2-minute 15% glycerol shock, fresh medium was added. Cells were harvested for assay of transient expression 36 hours later. The pSV ␤-galactosidase gene (Promega) was cotransfected as an internal control.
Statistics
Conventional methods were used for calculation of means and SDs. Coefficients of skewness and kurtosis were calculated to test deviations from a normal distribution. Logarithmic transformation was performed on the individual values of skewed variables, and a normal distribution of transformed values was confirmed before statistical computations and significance testing. Statview II 4.0 and JMP 3.1 software was used for statistical analysis.
Results
Polymorphic Sites in the MTP Promoter
A total of 184 healthy white men aged 30 to 45 years were recruited, 20 of whom were randomly selected for the search for polymorphisms in the MTP promoter. The entire group Selected Abbreviations and Acronyms apo ϭ apolipoprotein CAT ϭ chloramphenicol acetyltransferase EMSA ϭ electrophoretic mobility shift assay MTP ϭ microsomal triglyceride transfer protein PCR ϭ polymerase chain reaction was subsequently genotyped for the common polymorphisms found during the initial sequencing procedure and used for association studies. Two common polymorphisms were identified in the promoter region of MTP. One was a G3 T substitution at Ϫ493, and the other was an A3 T substitution at Ϫ400. Two less-common polymorphisms were also found at Ϫ410 (A/G) and Ϫ388 (A/G). The allele frequency for the MTP Ϫ493 G/T polymorphism was .75/.25 in the population of 184 native Swedish men. The corresponding figures for the MTP Ϫ400 A/T polymorphism were .68/.32. The population was found to be in Hardy-Weinberg equilibrium for the two polymorphisms. The combination of genotypes for the Ϫ493 and Ϫ400 sites within the group of 184 subjects is in shown in Table 1 .
Functional Studies of Polymorphic Sites
EMSA was performed to determine whether there was differential binding of nuclear protein(s) to the polymorphic sites that might regulate the transcriptional activity of the gene. By use of labeled, sequence-specific and excess, unlabeled nonspecific oligonucleotides, two factors (bands on the EMSA gel) showed sequence-specific binding to the MTP Ϫ493 site (Fig 1) , whereas the EMSA pattern did not differ between the two MTP Ϫ400 constructs. The first factor (factor A) bound to the MTP Ϫ493G allele as shown by a faint extra band. A second factor represented by a clear double band (factor B) appeared only with the Ϫ493 G allele. The EMSA pattern did not differ between the two MTP Ϫ400 constructs. No homology was found between the region surrounding the Ϫ493 G/T site and the binding sites for known transcription factors. A transfection assay was conducted to assess whether the allele-specific binding of nuclear proteins affected transcriptional activity of the MTP promoter. Two tandem copies of a 31-bp DNA segment containing either of the Ϫ493 G or T alleles were inserted upstream from a minimal and heterologous promoter driving the CAT gene. The minimal promoters were used to delineate the impact of putative transcriptional activators or repressors on the Ϫ493 G/T sites. Fig 2 shows the expression of the CAT gene in HepG2 cells. The promoter constructs harboring the Ϫ493 T site had an almost twofold higher transcriptional activity than the Ϫ493 G construct (ϩ187Ϯ69%, PϽ.05). The interpretation of this finding together with the EMSA pattern is that factor A and/or B could act as a transcriptional repressor. There was no difference in transcriptional activity between constructs containing either of the two Ϫ400 A or T alleles (Fig 2) . 
Associations With Plasma Lipoproteins
As the MTP Ϫ493 G/T polymorphism proved to be functional in EMSA and transfection assays, associations were sought between MTP genotype and plasma lipoprotein concentrations. Subjects who were homozygous for the rare Ϫ493 T allele had significantly lower LDL cholesterol and triglyceride levels than did either heterozygotes (Ϫ493 G/T) or homozygotes for the common allele (Ϫ493 G/G) ( Table 2 ). The effect of the MTP Ϫ493 T allele therefore seemed to be recessive. The LDL cholesterol concentration of the Ϫ493 T/T individuals was, on average, 22% lower than the LDL cholesterol concentration in carriers of one or two copies of the Ϫ493 G allele. Similarly, men who were homozygous for the Ϫ493 T allele also tended to have lower plasma total cholesterol values (Pϭ.06, compared with individuals with either the Ϫ493 G/G or G/T genotype). Otherwise, there were no differences in VLDL or HDL lipid concentrations according to MTP Ϫ493 genotype. Because body mass index may influence lipid and lipoprotein levels, they were recalculated according to genotype and after adjustment for body mass index in an ANCOVA. These latter results did not change from those found earlier, and we concluded that body mass index was not a confounder. The lipoprotein lipid levels were almost identical when subjects were grouped according to the MTP Ϫ400 A/T polymorphism (data not shown).
The apoE polymorphism exerts a major influence on plasma LDL cholesterol levels. A potential confounding effect of apoE genotype on the association between MTP genotype and LDL cholesterol level was eliminated by confining the MTP genotype-lipoprotein phenotype association studies to subjects homozygous for the E3 allele. In this group of 94 subjects, the respective mean LDL cholesterol concentrations for the three MTP genotypes were 3.70Ϯ0.73 mmol/L for Ϫ493 G/G (nϭ52), 3.83Ϯ0.95 mmol/L for Ϫ493 G/T (nϭ37), and 2.90Ϯ0.42 mmol/L for Ϫ493 T/T (nϭ5). These figures are very similar to those encountered for the whole group ( Table 2 ), suggesting that the Ϫ493 G/T polymorphism influences the LDL cholesterol concentration independently of apoE genotype.
The apoB content in VLDL subfractions was determined in five subject homozygous for the MTP Ϫ493 T allele and 10 subjects homozygous for the MTP Ϫ493 G allele. This procedure revealed marked differences in the relative amounts of apoB in large versus small VLDL despite a fairly unchanged total VLDL triglyceride level (Table 3 ). The apoB level in large VLDL was 50% lower in MTP Ϫ493 T/T subjects than in MTP Ϫ493 G/G subjects. The corresponding VLDL apoB reduction was even more prominent in the fraction containing small VLDL, in both absolute and relative terms (Ϫ60%). The lowering of apoB was more pronounced than the lowering of triglycerides, indicating that each VLDL particle carried more triglyceride molecules. There was no difference in apoB content of the IDL fraction. The LDL apoB level was lower in MTP Ϫ493 T/T subjects, but this reduction was proportional to the initial observation of a lower LDL cholesterol level.
Discussion
Polymorphisms in the promoter region of MTP have not been previously reported. We have detected a common G/T polymorphism located 493 bp upstream from the start of the transcription site for the MTP gene. The rare allele, with an allele frequency of Ϸ.25, confers significantly higher transcriptional activity. Healthy homozygotes for this genetic variant, comprising Ϸ6% of healthy, white, middle-aged Swedish men, have a low LDL cholesterol concentration in plasma.
The difference in LDL cholesterol concentrations between carriers of the MTP Ϫ493 G/G or G/T genotype and carriers of the MTP Ϫ493 T/T genotypes is Ϸ0.8 mmol/L. The impact of homozygosity for the MTP Ϫ493 T allele on cardiovascular risk is therefore likely to be of major significance. Law and colleagues 21 calculated that a 0.6 mmol/L reduction in the serum cholesterol level would correspond to a 50% lowering of the risk of future ischemic heart disease in 40-year-old men. According to the Framingham score, the 10-year risk of developing cardiovascular disease would be 25% lower in subjects with an MTP Ϫ493 T/T genotype. 22 MTP has a pivotal role in controlling the secretion of apoB-containing lipoproteins, as MTP fills the immature VLDL particle with lipids before it is secreted.
1 Poor lipidation of VLDL leads to intracellular degradation instead of secretion. 23 Suppression of MTP function by specific MTP inhibitors leads to reduced secretion of VLDL, 4, 5 and it is likely that a major proportion of apoB is degraded under such circumstances. However, inhibition of MTP must be quite extensive to have an effect in vivo, as obligate heterozygotes for MTP deficiency (fathers or mothers of patients with abetalipoproteinemia) have a fairly normal plasma lipid and lipoprotein pattern. 8, 24, 25 It is more difficult to speculate about the physiological effects of stimulated MTP function. In the present work, we describe a common variant of the MTP promoter leading to enhanced transcriptional activity of the gene. Furthermore, healthy human homozygotes for the rare allele had a considerably lower LDL cholesterol concentration. Which mechanisms could link increased MTP expression to lower plasma LDL cholesterol levels in humans? The LDL cholesterol concentration depends on the balance between the rate of LDL synthesis and the rate of removal of LDL particles from plasma. The regulation of the secretion of apoB-containing lipoproteins from the human liver is not completely understood. ApoB synthesis seems to be almost constant, irrespective of metabolic status. 23 In contrast, increased availability of lipid substrate (mostly triglycerides) leads to increased secretion of preferentially large and lipid-rich VLDL and to decreased intracellular degradation of immature VLDL particles. 23 Once in the circulation, the larger VLDL species are lipolyzed by lipoprotein lipase, and most of the remnant particles formed in this process are removed from the circulation before reaching a particle size or density corresponding to LDL. 26 Small VLDL particles, on the other hand, seem to be direct precursors of LDL, as the secretion rate of small VLDL is tightly linked to the LDL cholesterol concentration in plasma. 27 It could thus be speculated that enhanced function of MTP, as would occur with the rare MTP Ϫ493 T promoter variant we have described, acts by shifting the balance between secretion of large and small VLDLs. If MTP activity is increased, then lipidation of immature VLDL particles will be more efficient, and it is likely that an increased proportion of larger VLDL species will be secreted. These particles are, however, not direct precursors of LDL, and the input from the VLDL to the LDL fraction will decrease, thus accounting for the lower LDL cholesterol levels seen in individuals with the MTP Ϫ493 T/T genotype. The distribution of apoB within the VLDL subfractions argues in favor of this concept. The marked reduction of small VLDL apoB could reflect lowered secretion of this VLDL species, which would lead to diminished production of LDL. The higher VLDL particle content of triglycerides indicates that larger VLDL particles are secreted. Obviously, the secretion pattern of VLDL cannot be elucidated from a single analysis of fasting plasma levels of VLDL, but the relative triglyceride enrichment of the VLDL particles argues in favor of hepatic secretion of larger but fewer VLDL particles in the situation with high MTP expression.
Although the hypothesis of ascribing to MTP a role in the secretion of VLDL that regulates the LDL level in plasma is attractive, it must be borne in mind that the plasma LDL cholesterol level in humans is very much dependent on the expression of hepatic LDL receptors and by them, the removal pathway of LDL. This effect is clearly demonstrated in familial hypercholesterolemia, in which half of the functional LDL receptors are lacking in the heterozygous patient. As a consequence, the LDL cholesterol level in plasma is twofold to threefold above normal levels. The question arises whether high expression of MTP could lead to an alteration of intracellular cholesterol homeostasis. As MTP is also transferring cholesterol, 28 an elevated MTP activity would lead to a depletion of cholesterol from intracellular stores. This would, in turn, be sensed by sterol-regulated binding proteins acting on the promoter of the LDL receptor gene. 29 Perturbation of intracellular cholesterol homeostasis secondary to elevated MTP activity is likely to be sensed in a fashion similar to 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition, in which upregulation of LDL receptors is the key mechanism underlying the lowering of LDL cholesterol in plasma.
Previous characterization of human and hamster MTP promoters revealed no regulatory regions upstream from Ϫ239 bp from the transcriptional start site. 10 This does not, however, rule out the possibility of a regulatory region at Ϫ493, as stepwise promoter deletions may include both enhancing and repressing regions, and second, it is not known whether Hagan et al 10 used a human clone with a Ϫ493 G or T.
In summary, we have shown that a novel, common polymorphism in the promoter region of MTP is of functional importance in regulating expression of the MTP gene and influences the LDL cholesterol concentration in plasma in healthy, middle-aged men. These findings add to our understanding of how the plasma LDL cholesterol level is regulated and suggest that genetic variation in MTP expression may have important implications for the development of cardiovascular disease in humans.
